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INTRODUCTION

There are few subjects of greater importance to the development of
biotechnology than the issuance of patents. Therefore, I was disturbed to
hear Dr. Edward Penhoet's comments about the twenty-year patent term.'
This is one of the things I am going to address in this discussion, which
addresses the major issues in biotechnology facing the U.S. Patent and
Trademark Office (PTO). Indeed, there are a number of major issues
regarding biotechnology facing the Patent and Trademark Office, and I think
that one could reverse that by saying that some of the principal issues facing
the biotechnology industry have to do with not only the PTO, but the whole
question of patenting in general.
Obviously, patenting is a very important part of commercializing
biotechnology. The biotechnology industry requires considerable capital
expenditure, not only for the initial research and development, but also to go
through the regulatory approval process necessary to get a
product-particularly a pharmaceutical product-on to the market.2 That
capital is essential and the ability to get that capital is very much dependent
upon the capacity to get patent protection for a prospective product.
The first thing that must be understood, but which is unfortunately often
forgotten, is that patent protection in the United States is patent protection,
yes, but we are in a global economy. This means that products with patent
protection in the United States will not necessarily receive patent protection
on a global basis. Effective and timely patent protection in the United States
may give a U.S. based innovator the capital necessary to continue without his
research and develop a marketable invention. However, from a larger
national policy perspective, it is no good to make American consumers pay
by respecting the patent monopoly for the research and development costs of
a particular product, only to give it away to the rest of the world for free.
This is very important to remember, and I think American consumers have
limited tolerance for this practice. Indeed, we often see that limit when
particular fruits of biotechnology or other types of medical and pharmaceuti-

1. Edward Penhoet, Ph.D., Science & Technology Policy: A CEO's View, 33 CAL. NV. L.
REV. 15, 23-29 (1996) (this volume). Prior to June 8, 1995, the term for a patent issued in the
United States was seventeen years from the date of the patent grant. The implementing
legislation under the General Agreement on Trade and Tarrifs (GAI) amended 35 U.S.C. §
154(a)(2) to change that term to one of twenty years from the date of filing the original
application.
This change takes into account the prosecution process of the patent; if the process takes
less than three years, the patent holder will receive a longer patent term under the new twentyyear term than he otherwise would have under the old seventeen-year term. On average, only
5% of the patent applications take more than three years, though biotechnology patents are
among the slower applications. Kenneth J. Burchfiel, U.S. GAIT Legislation Changes Patent
Term, 77 J. PAT. & TRADEMARK OFF. SOC'Y 222-224 (1995).
2. It takes an average of $359 million and about 10 to 12 years to bring one new
pharmaceutical to market. James B. Silberman, The North American Free Trade Agreement
Effects on PharmaceuticalPatents: A Bitter Pill to Swallow, 12 J. CONTEMP. HEALTH L. &
POY' 607 (1996).
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cal research become very expensive. Therefore, we see a lot of pressure for
early generic products to come on the market and for public policies that
This trend, which is counterproductive to our
permit that to happen
industry, is likely to continue in the absence of a system that provides the
same degree of protection globally for biotechnology products as we have
here in the United States. This is at the core of the twenty-year patent term
issue. Before I get into that subject more thoroughly, however, I want to
highlight some of the other issues this Article addresses.
The question of an effective patent term is clearly a very important issue
in the biotechnology area, but there are many other issues that also affect our
handling of biotechnology products in the PTO. The first time I ever went
to the University of California at San Diego, we held hearings on our utility
guidelines for examining biotechnology patents in the Patent and Trademark
Office. One of the criteria for gaining a patent in the United States is that an
invention must be novel,4 non-obvious,5 and useful.6 As a result, one must
outline in his application what the utility, or usefulness, of the product is
going to be. This has raised many problems in the area of biotechnology in
recent years,7 but I think we have effectively moved to resolve those
problems. Still, the utility issue remains a very important issue.
In addition to utility, it seems like once we resolve one issue, another
comes down the pike. For example, we are now starting to receive a sizable
number of applications seeking patent protection for the genome sequencing
emerging from the large genome sequencing projects. 8 These applications
raise practical questions, as well as difficult policy issues. We had hearings
related to some of those practical issues just three weeks ago at the University
of California, at San Diego.9
Furthermore, there is a much larger policy question that hangs over the
whole future of the biotechnology industry. This is the question of the extent

3. See Michelle S. Marks, The Impact of the Patent Term Provisions of the 1994 Uruguay
Round Agreements Act on the Drug Price Competition Patent Term and Restoration Act, 51
FOOD & DRUG L.J. 445, 449 (1996) (explaining that the Hatch-Waxman Act promotes the

availability of generic drugs by allowing studies to be conducted before the expiration of the
patent term. This promotes the public policy of reducing the costs of drugs for consumers.).

4. 35 U.S.C. § 102 (1984).
5. 35 U.S.C. § 103 (1984).

6. 35 U.S.C. § 101 (1984).
7. Notice of Public Hearing and Request on Patent Protection for Biotechnological
Inventions, 59 Fed. Reg. 45267 (1994). The PTO was seeking public input to help insure it was
properly construing and applying statutory requirement of patentability, particularly those that
depend upon evaluation of skill levels in field of biotechnology. Also, the PTO asked for input
regarding sufficient legal standard that are clear and appropriate for biotechnology inventors.
8. Dr. Craig Venter led one of the more prominent of these projects. On May 24, 1995, he
and another scientist announced that for the first time, a complete DNA sequence of a free-living
organism had been decoded. The sequence is the entire genetic code of the bacterium HemophiIns influenzae. Nicholas Wade, Bacterium's Full Genetic Makeup is Decoded,N.Y TIMEs, May
26, 1995, at Al.
9. E.g., Notice of Hearings and Request for Comments on Issues Relating to Patent
Protection for Nucleic Acid Sequences, 61 Fed. Reg. 9980 (1996).
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to which we are going to continue to patent life forms.'" It is unclear what
role we in the PTO will play in answering this question. I am not certain that
such a role is something that I have any control over directly, one way or
another, because it is ultimately in the control of Congress. This is certainly

a large international issue, and I must say, it gets my blood boiling to hear
Eileen McMahon's remarks" that a major trading partner, Canada, with
whom we are supposed to have reasonable relationships, has already
embarked on seeing that all the fruits of U.S. research in this area will be in

the public domain. 2

This leads me into the final issue, which is the international system that
overlays all these other issues. The international system is related to each and
every one of the previous issues, but it is also a issue standing on its own.

We are very much in the biotechnology era, an era in which we have made
much progress toward common international standards for the protection of
intellectual property 3 ; however, there are still many questions lingering
around other places in the world as to whether those new standards are even
going to apply. It is even unclear as to whether the standards developed in
the Uruguay Round Implementing Act, 4 such as the TRIPS agreement, 5 are
even going to apply on an international level.
PATENT PROTECTION IN A GLOBAL ECONOMY:

THE TwENTY-YEAR

PATENT TERM ISSUE
The twenty-year patent term issue has two sides. First, there is the
question of the twenty-year term from filing and its implications for the
biotechnology industry. The United States, as part of the Uruguay Round
Implementing Act enacted over a year ago last December, went from a patent
term of seventeen years from the date of the issuance of the patent to a term

10. See Diamond v. Chakrabarty, 447 U.S. 303 (1980) (holding that a live, human-made
organism may be patented under 35 U.S.C. § 101).
11. See Eileen McMahon, NAFTA and the Biotechnology Industry, 33 CAL. W. L. REV. 31,
33-36 (1996) (this volume). See also Eileen McMahon, Nucleic Acid Sequences and Other
Naturally OccurringProducts: Are the Patentedin Canada, 10 CAN. INTELL. PROP. REV. 11
(1993) [hereinafter McMahon, Nucleic Acid Sequences].
12. McMahon, Nucleic Acid Sequences, supra note 11, at 11.
13. General Agreement on Tarrifs and Trade Multilateral Trade Negotiations (The Uruguay
Round): Agreement Establishing the Multilateral Trade Organization (World Trade Organization), Dec. 15, 1994, 33 I.L.M. 13; Agreement on Trade-Related Aspects of Intellectual Property
Rights, Including Trade in Counterfeit Goods, Apr. 15, 1994, 33 I.L.M. 1197; Final Act
Embodying the Results of the Uruguay Round of Multilateral Trade Negotiators, Apr. 15, 1994,
33 I.L.M. 1125.
14. Final Act Embodying the Results of the Uruguay Round of Multilateral Trade
Negotiations, Apr. 15, 1994, 33 I.L.M. 1125.
15. The Agreement on Trade-Related Aspects of Intellectual Property Rights, Including
Trade in Counterfeit Goods, opened for signature, Apr. 15, 1994, 33 I.L.M. 1197. TRIPS
established minimum international standards and rule for intellectual property protection as well
as minimal procedural norms for enforcement.
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of twenty years from the filing of a patent application.1 6 This change is
what many people identify as the key issue when they discuss patent terms.
The second issue regarding the patent term is a subspecies of the change
in term, which is also somewhat controversial. Although it concerns fewer
people, the people it does concern are very concerned about it. This issue is
how we in the U.S. PTO and the FDA are interpreting the transition period
from the seventeen-year issuance system to a twenty-year from filing system;
and particularly, how that relates to the administration of the so-called HatchWaxman Act" and the Patent Term and Drug Price Competition Act of
1984.18 I suppose that raises the question of whether the Patent Term and
Drug Price Competition Act should even be revisited.
The reasons why we in the United States have chosen to adopt a term of
twenty years from filing are extremely sound. First, we were virtually the
only country in the world that did not measure the patent term twenty years
from filing. When I first became involved in this subject matter many years
ago, I asked the question, "What's the difference between the twenty-year
term that everybody else has and our seventeen-year term?" The answer I
received was, "Not much, because it takes you three years to get through the
PTO here." A few months or a year or two may be the practical difference,
but the practical effect is the same. In Germany, you have three years to get
through the patent office and then you have seventeen years of patent
protection. In the United States, you have three years to get through the
PTO, and then you have seventeen years of patent protection. In either case,
the protection comes out to twenty years.
Industry reliance on these time frames is so strong that there was a major
negative reaction when patent processing times started to creep up to an
average of about 36 months in the 1980s, causing many patents to take longer
than 36 months from the time they were filed to issue. In response to this
problem, we began restructuring the PTO so as to decrease pendency and so
that, as a practical matter, no patents would take longer than 36 months to
issue. Indeed, that project was extremely successful. Today, in the U.S.
PTO, the average pendency for a patent is 19.1 months. Although there was
no incentive to process an application in less than 36 months prior to the
enactment of the Uruguay Round, other than just doing our job quickly, there
was no effective loss of patent term if it did take longer than 36 months to

16. 35 U.S.C. § 154(a)(2) (1996).
17. 35 U.S.C. § 156 (1996) (requiring that restoration extension of a patent term for delay
caused by the Food and Drug Administration (FDA) approval process not preclude application
of restoration extension to patent term changed from seventeen years after issuance to twenty
years, pursuant to the Uruguay Round Agreements Act); Merck & Co., Inc. v. Kessler, 80 F.3d
1543 (1996) (confirming that a patent with aterm of twenty years from filing pursuant to URAH,
could also be extended through the restoration expansion provided by the Hatch-Waxman Act
due to delays in the FDA approval process).
18. Patent Term and Drug Price Competition Act of 1984, Pub. L. No. 98-417, 98 Stat.
1598 (codified as amended at 35 U.S.C. § 156) (1984).
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issue a patent.19 Therefore, if a person wanted to drag out the process, and
some people did, they could do so.2" Even so, the statistics show that at the
time we shifted to the new system, less than 5% of U.S. patents were issued
in a time period greater than 36 months after filing. Thus, only a very small
group of patents cannot be processed in 36 months.
There are some who criticize the twenty-year term. Some fear that they

will lose patent protection because we will not be able to issue a patent within
36 months. Therefore, they will have less patent time than the traditional
seventeen years. Our response to this fear is that 5% is a fairly manageable
number.2 ' We are in the process of re-engineering our systems in the PTO
so that we can virtually guarantee that no patent will take longer than 36
months to process.22 Thus, everyone will have at least seventeen years of
protection.23 As a practical matter, most patent applicants will have more

19. G. Lloyd Knight, An (UN)Intended TransitionalProvision in the GA7T Act-20 Years
from When?, 77 J. PAT. & TRADEMARK OFF. Soc'V 717 (1995). Before implementation of
twenty year inclusive term, the seventeen year term started from the date the patent was issued.
Therefore, if it took longer than thirty-six months to enact a patent, there was no loss of the
seventeen year patent term.
20. The strategy behind dragging out the process is that the term does not begin to toll until
the clinical trials are complete.
21. I understand the position of those who have a particular patent pending, which they have
put their hearts and souls into, as well as all their money and all their friends' money. For them,
nothing is more important than that patent. But the real issue here is the relationship between
the patent examining process and the regulatory approval process in the FDA. It is simply a fact
that in these cases where there are particular approval problems, such as financing or the
wherewithal to engage in the testing, a very convenient tool to drag out the issuance of the patent
and therefore extend your patent term without having to deal with Hatch-Waxman, was to file
continuances in the PTO. Every single major user group of the PTO from the National
Association of Manufacturers to the Electronics Industry Association, the Software Publishers
Association, the American Intellectual Property Association, the American Bar Association,
intellectual property law section and on and on and on, has asked us and the Congress to go to
a twenty-year term because their interest, uniformly, is in having a common international
standard so that patents cannot expire at different times in the United States than when they
expire abroad. No electronics company wants to be in a position where a competitor's patent,
many times a foreign competitor's patent, expires three years earlier in Japan or Germany than
it does in the United States. Then, they are prohibited from using that as public domain material,
which their foreign competitors can do, and they have their hands tied behind their back. We
have to look at what the majority of American industry is saying.
22. In the event that the PTO does not diligently prosecute a patent application, the bills
currently pending on Capitol Hill provide for an extension of the patent. This technique is more
effective because it is not simply a one-size-fits-all system that prejudices 90% of the other hightech industries in America, putting them at a competitive international disadvantage. H.R. 3460,
104th Cong., 2d Sess. (1996); H.R. 1733, 104th Cong., 2d Sess. (1995).
23. Some of the new measures are as follows:
Under this legislation, the total duration of all extensions shall not exceed 10
years. To the extent that periods of delay overlap, the period of any extension granted
shall not exceed the actual number of days the issuance of the patent was delayed;
No Patent shall be extended that has been issued before the expiration of 3
years after the filing date of the application leading to the patent or the commencement of the national stage, whichever is later, not taking into account the benefit of
any earlier filing applications of this title;
The period of extension of the term of a patent under this subsection shall be
reduced by a period equal to the time during the processing leading to the patent in
which the applicant failed to engage in reasonable efforts to conclude processing or
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protection.2 4 For the vast majority of U.S. patent applicants, the Uruguay
Round Implementing Act amendments extended their patent terms.25 We
will have longer patent terms than we had before. Therefore, if we were to
try to reverse the Uruguay Round Implementing Act amendments and return
to the old system, a lot of people would object. In fact, it probably would
have become a subject of former-Senator Dole's takings legislation26 that he
was going to send to the Senate floor, claiming that we would be taking away
people's property rights. People certainly would not like such a reversion at
all. Indeed, nothing illustrates this more than the fact that one of the most
controversial sub-issues in this larger patent term issue is the question of the
impact of the transition rules in the Uruguay Round Implementing Act on
certain patent applicants. There were more than twenf' pharmaceutical
companies whose patents were issued prior to 36 months originally and,
therefore, received longer initial patent terms under the new system. When
the extensions provided under the Hatch-Waxman Ace 7 were added to the
patent term, they gained even longer protection.28 When we in the PTO

decided to run the Hatch-Waxman extensions from the seventeen-year term,
examination of the examination.
H.R. 1733, 104th Cong. 2d Sess. (1995).
The total duration of any extensions shall not exceed 10 years. To the extent
that periods of delay overlap, the period of any extension granted shall not exceed the
actual number of days the issuance of the patent was delayed;
The period of extension of the term of a patent shall be reduced by a period
equal to the time in which an applicant failed to engage in reasonable efforts to
conclude prosecution of the application;
No patent the term of which has been disclaimed beyond a specific date may
be extended under this section beyond the expiration date specified in this disclaimer.
H.R. 3460, 104th Cong., 2d Sess. (1996).
24. H.R. 1733 would weaken the patent system by mandating that a patent term will be
measured by the filing date agreed to in the GATT agreement. "It scraps the 17-year patent
protection in favor of a 20-year term extending from the day an application is filed. Under this
arrangement, a patent that takes 15 years to grant-and many technical patents requires an
extensive review process-would be entitled to only 5 years of protection." 142 CONG. REC.
7137-01 (1996) (statement of Rep. Forbes).
25. Id.
26. S. 22, 104th Cong., 1st Sess. (1995).
27. To qualify for an extension under the Hatch-Waxman Act, a patentee much provide the
PTO with evidence of the actual amount of the patent term consumed during the premarket
approval process. The act established a 5-year limit on the extension, which applies irrespective
of the actual loss of the patent tenn. For patented human pharmaceuticals and food or color
additives, which had entered the regulatory approval process prior to the date of the enactment
of the Act, the maximum extension was set at 2 years. In any case, however, the overall patent
term cannot exceed 14 years from the time of FDA approval. S. REP. No. 414, 102d Cong., 2d
Sess. (1992).
28. In 1836, the Patent Act was rewritten and the new law authorized a 7-year patent
extension upon a showing by the holder that, without fault or negligence on his part, the patentee
had failed to obtain reasonable remuneration for his time, ingenuity, and expense. Extensions
were generally granted when the federal government was the cause of, or contributed to, the
failure to be able to take advantage of the patent. Therefore, the Hatch-Waxman Act stretched
out the overall patent term to 14 years. S. REP. No. 414, 102d Cong., 2d Sess. (1992).
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and not from the twenty year term, we were sued by those companies-and
we recently lost in that litigation. 9 At least, we lost initially in the district
court and the Court of Appeals for the Federal Circuit. There is still an open
question as to whether we will appeal that decision to an en banc reconsideration in the Court of Appeals for the Federal Circuit, or even possibly file a
petition for certiorari in the U.S. Supreme Court. Nevertheless, this proves
that there are at least twenty large pharmaceutical companies out there that
do better under the twenty-year term than they would have done under the
old seventeen-year term.
When we begin talking about months and twenty-year terms, the HatchWaxman Act, the Uruguay Round Implementing Act, and everything else, it
becomes quite complicated. But the real issue here is the issue of under what
circumstances should delay, either in the issuance of a patent or in the
effective ability to utilize the patent, be recognized in the context of patent
term restoration?" This is the real issue. Presumably, if Hatch-Waxman
and the 1984 Patent Term Restoration and Drug Price Competition Act were
working, at least in the manner that many biotechnology innovators would
like them to work, there would be no concern at all. If the FDA took a long
period of time to approve a product, they would have relief in the form of an
extension of their patent. So, when people criticize the twenty-year term,
they are really criticizing their inability to take advantage of a "loophole" in
the law that was provided earlier. This loophole allowed them to stall in the
PTO, so that in getting a patent issued, quite apart from the congressional
policies specifically mandating patent term extensions in certain cases where
there is a very long FDA approval period, they would get an extra extension
that we would create because they were "futzing" around in the PTO and
delaying the process. That is the behavior we are talking about here and I
think we have to be very clear about that.
If that is the issue, then my response is that it is inappropriate to
prejudice 99% of the users of the PTO, as well as all of the other users of the
intellectual property system who want a very secure twenty-year term from
filing, simply to provide this extra advantage to the biotechnology industry.
If there is a case to be made for longer patent terms for the biotechnology
industry and the 1984 legislation is inadequate, then we should focus on that
and amend that legislation to resolve the problem.
That pretty much describes the patent term issue and I think it is wishful
thinking to believe that it will change. There is legislation pending on
Capitol Hill to modify the 1994 legislation, the Uruguay Round Implementing

29. Merck & Co., Inc. v. Comm'r of Food and Drugs, 80 F.3d 1543 (Fed. Cir. 1996).
30. Id. Patent term restoration is the term used when a patent, which has expired because
of delays in obtaining FDA approval, is restored. With respect to any restoration period granted
after June 8, 1995, this fourteen-year limitation will be part of the calculation of the permissible
number of days of the restoration extension. Id. at 1551. A patent in force on June 8, 1995, is
entitled to have restoration extension, whenever granted, added to the term of either seventeen
years from issuance or twenty years from filing. Id. at 1553.
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Act, but I would not count on its passing. I do not believe that legislation
will pass; it has not passed yet. I think the twenty-year term from filing is
here to stay. Therefore, we should focus on what the real issues are and not
go back to the old system.
REINVENTING GOVERNMENT: UTILITY GUIDELINES
The next set of issues, which is perhaps a little less cosmic but very
important, is the question of utility guidelines. I think this is a good example
of our doing good government, reinventing government. I believe these
reinventing efforts will continue, but it was very clear when I came into the
PTO three years ago, that there was still a very large residue of old thinking
in the PTO. This thinking was that the role of a patent examiner is to create
hurdles that a patent applicant had to cross and that if you were really clever
and developed some nice hurdles and the applicant was able to jump over
them, then he deserved a patent. It was a very adversarial proceeding. In
fact, I remember at one point in my career many years ago, someone referred
to the prosecution of patent applications at the PTO as ex parte litigation.
That is certainly not the way in which we in the Clinton administration are
proposing to do business.
There are legal standards for the patentability of virtually every invention
that is proposed to the PTO." The only issue for us is to determine whether
the applicant has met those standards. If he has not, then we help him try to
meet those standards where we clearly can, and then get him out of the PTO
as quickly as possible and into the marketplace where he can get venture
capital and strengthen our economy by making his invention into new
products that are going to make us globally competitive and put people to
work. That is our function.
Ironically, in the biotechnology area, we have found reforms that we had
made which were initially thought to be positive, turned out to exacerbate the
old thinking. That is, if you projected yourself back ten years ago when the
biotechnology industry was really growing, we did not have an adequate
examining staff in the PTO to handle these very high-technology applications.
We had a lot of people with B.S. degrees in chemical engineering, who were
trying to examine patents in this very complicated recombinant DNA-based
technology. We moved to fix that. We are very proud of the fact that we
now have approximately 150 Ph.D.s examining biotechnology applications,
many with post-doctoral work. In this sense, our office is unique in
comparison with the rest of the world.
Unfortunately, when we hired all of these great Ph.D.s, we were so busy
that we put them right to work without telling them much about the patent
system. As a result, we began to see that the PTO procedures looked more
like oral examinations for Ph.D.s in biotechnology and that we were engaging

31. See 35 U.S.C. §§ 101-103 (1984).
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in peer review rather than patent examination. So, we moved to correct that
problem. We held hearings in California and in Washington and heard from
people in the biotechnology industry. And we wrote a new set of guidelines32 to guide examiners and then trained them on how to apply the law.
As a result, we have seen a very substantial reduction in the number of rejections. In fact, our data shows that before the guidelines were issued, utility
rejections under section 101 of the United States Code33 were made in about
5.9% of the applications. After we issued our final guidelines, such rejections
dropped to a mere 1.9% of the applications, one-third the previous number.
Obviously, that is good news to a lot of people. Not only is it good news to
the people who are now getting through the system who were not before, it
is also good news for everybody else because those examining resources will
be put where they are needed and not engage in needless activity.
The essence of the utility guidelines was that we were getting ourselves
into a problem that is actually somewhat related to the FDA. That is to say,
if you take a strict constructionist view, you do not know whether a
pharmaceutical or biotechnology invention is really going to be useful until
you have gone all the way through the human testing process. The essence
of our work was to avoid that. That would obviously be a completely
unworkable situation. For example, if you published your results, but did not
subsequently file a patent application in the United States within twelve
months, you would never be able to patent your work. Instead, it would go
into the public domain. In the rest of the world, work goes into public
domain if you publish without having first filed an application. You would
be placed in a terrible position if you had to make your work available and
go through the testing, all of which would be available to the public; neither
would you able to file the patent application until maybe five or six years
later.34 If this were the case, then nothing could be patented. This was
obviously not the intention of the law.
To avoid the paradox just described, we now look at the affidavits filed
with the applications and give consideration to the expert opinions assuring
some reasonable expectation that the technology proposed will be useful.
This is simply a question of applying common sense to our procedures and
utility guidelines. Let me say, though, there are those who would like to
suggest that almost any representation made to the PTO should be accepted
at face value and that we should issue a patent on everything. This clearly
is not the case. There are always going to be people who will be disappointed. We hear that some people feel that section 112 rejections, enablement

32. Utility Examination Guidelines, 60 Fed. Reg. 36,263 (1995).
33. "Whoever invents or discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof, may obtain a patent
therefore, subject to the conditions and requirements of this title." 35 U.S.C. § 101 (1996).
34. The delay would occur because it would take this long for the applicant to accumulate
enough data to satisfy the utility requirements for a patent.
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rejections," are being substituted by some examiners for the utility rejections36 that they used to make.37 Indeed, we found this to be the case in

some situations and we have moved to correct that, but enablement, being
able to describe how you enabled use of the invention, is a very important
aspect of patent law and we cannot give that up completely.
Maybe that is a good way to lead into the next issue, genome sequencing,
particularly the human genome sequencing 8 applications.
GENOME SEQUENCING APPLICATIONS
This is an issue that might have ripened earlier, had not the National
Institutes of Health (NIH) in the person of Harold Varmis, the director of the

NIH, made a decision very early in his tenure to withdraw the applications
that the NIH had presented before the PTO. That decision, I think, was really
made on policy grounds and there is a serious policy question hanging over
this area. Obviously, the role of the patent system is to encourage innovation. 9 It is not to create a tollgate to innovation. There is a question in

many people's minds, certainly those in the scientific community, as to
whether the patent applications which are being filed for this particular

technology do not operate as tollgate type patents for further research, as
opposed to incentives for innovation. 0 This is something we will be
examining more closely in the future.
This also raises the especially practical problem that these applications
are enormously difficult to process. Simply running the genome sequences

35. Section 112 requires that a specification shall contain a written description of the
invention as well as the manner and process of making and using it. The specification must be
in such full, clear, concise, and exact terms as to enable anyone skilled in the art to which it
pertains to make and use the invention. 35 U.S.C. § 112 (1996).
36. U.S. CONST. art. I, § 8, cl.
8; 35 U.S.C. § 101 (1996).
37. Rejections which assert that an invention is inoperative, and therefore lacking utility
under 35 U.S.C. § 101, are often accompanied by rejections which assert that the specification
is not "enabling" under 35 U.S.C. § 112. The problem with Section 112 is the requirement that
the inventor's disclosure enable any person "skilled in the art" to make and use the claimed
invention. There is some controversy as to the meaning of "skilled in the art" for the purposes
of analyzing utility and enablement. The lack of precision concerning the meaning of "skilled
in the art" has led to criticism of inconsistent standards. Nada Jain, To Patent or Not to Patent:
Gene Therapy in the European Union and the United States, 4 CARDOZO J.INT'L & COMP. L.
103, 129 (1996).
38. The aim of human genome sequencing is to discover and document the entire genetic
make-up of the human body. Sequencing of genomes is best described as the unraveling of
information, that is the genetic code, contained within each human gene. Charles DeLisi, The
Human Genome Project, 76 AM. SCIENTIST 488 (1988).
39. The United States Constitution grants Congress the power "To promote the Progress of
Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive
Right to use their respective Writings and Discoveries." U.S. CONST. art. I, § 8, cl. 8.
40. Dr. Varmis' decision to withdraw the NIH applications from the PTO is telling. Perhaps
it was feared that the filing of these patents would infringe on subsequent research due to the
complexity of this field and the difficulty of drawing distinct boundaries at this early stage of
research. Without more precision and clear definition of the boundaries, these early patents may
have preempted subsequent filings and had a chilling effect on future research.
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through the computer takes months of computer processing time. It will
literally tie up our mainframe computers at the PTO and we will not be able
to do any other patent applications. There are also questions of cost. We had
hearings about this and received many recommendations as to how we can
deal with this practical problem. We are still sorting through those recommendations, but we are going to have to come to terms with them.
U.S. REGULATORY AFFAIRS IN THE INTERNATIONAL CONTEXT

Finally, I would like to revisit the larger question, the international
context for all of this. I am, as a public official, responsible for seeing that
the United States has a regulatory and legal framework that assures the
greatest possible economic growth and puts our society in the most competitive global position possible. This is extremely important in a period in
history where the two most significant factors affecting our society are
technology and the globalization of the economy. We cannot look at any
problem in the United States, particularly if it concerns technology, without
considering its global implications.
We have made a great deal of progress in getting basic recognition for
intellectual property rights in countries around the world, as well as basic
recognition for intellectual property rights, particularly in pharmaceutical
technology. Nevertheless, the nature of the world is such that we always
seem to be trying to catch up; history moves ahead faster than we can follow.
That is very true in this area. I see us already headed toward yet another
trade crisis within a few years if our foreign colleagues decide to diverge
from us and decide that they will not patent life forms. If they decide to treat
biotechnology differently than the United States does, we are going to have
a major trade problem. That is simply unacceptable to the United States. We
cannot have our people subsidize biotechnological research for the rest of the
world and, at the same time, diminish the value of this investment as an asset
in international trade. People cannot expect us to import automobiles and
timber from Canada or textiles from China and then allow these countries
simply to expropriate the fruits of our biotechnological research.
CONCLUSION

One of the many things we must do is to move in the direction of other
countries-this is one reason why we adopted the twenty-year patent term;
but we must expect them to come halfway as well. One of the issues that
will clearly be on the table, an issue we have already started to discuss, 4 is
the terms and conditions under which we will patent biotechnological research
around the world. Our professional colleagues in Europe are very much on
41. In fact, in May 1996, 1 discussed this issue with officials from New Zealand and
Australia, as well as with Artpad Bosch, the Director General of the World Intellectual Property

Organization.
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the same wavelength as we are, both in the European Patent Office and in the
European Commission. Although the European Parliament rejected a draft
directive by the European Commission 2 to deal precisely with this problem
of biotechnology, they are considering a new directive. Those rejections stem
largely from a total misconception of what the patent system is all about. We
are not proposing to make slaves of a particular group of people whose
genetic material may have been used in research. All we are proposing is to
do what we have always done: provide for a novel, non-obvious, and useful
innovation which has never before existed in the history of the world. We
want to give a very limited period of commercial exclusivity to a fruit of the
human mind, something that an individual has come up with so that his
investment in that effort can be recouped. If this is not provided, the
consequence will be that such useful innovations will be stifled.
In the short term, such stifling may be good for the United States. We
will see more research conducted in the United States and the world's
biotechnology industry increasingly concentrate here. However, this is not
acceptable in the long-term because though it is wonderful to have all these
new inventions in the United States, we cannot (and will not) subsidize the
creation of biotechnology for the rest of the world.

42. Council Regulation 2641/84 of 17 September 1984 on the Strengthening of the Common
Commercial Policy, 1984 O.J. (L 252) 1. Council Regulation 2641/84 was enacted to defend the
legitimate interests of the European Union and to ensure that the Community acts with as much
speed and efficiency as it trading partners. In both the United States and the European Union,
there appears to be a general consensus that the development of biotechnology is dependent on
the co-evolution of biotechnology and patent law. See Jan, supra note 37, at 129, 130.
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